Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

Plans and Pricing

DrugPatentWatch Archives

You are currently viewing the 2008 archives
Click here to return to the current data set

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: LOESTRIN 24 FE

« Back to Dashboard
Loestrin 24 Fe is a drug marketed by Warner Chilcott and is included in one NDA. It is available from two suppliers. There is one patent protecting this drug and one Paragraph IV challenge.

The generic ingredient in LOESTRIN 24 FE is ethinyl estradiol; norethindrone acetate. There are twenty-six drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norethindrone acetate profile page.

Summary for Tradename: LOESTRIN 24 FE

Suppliers: see list2
Formulation / Manufacturing:see details

Clinical Trials for: LOESTRIN 24 FE

Study of Loestrin 24(24 Days of "Real" Pills) Fe Versus Loestrin 1/20 (21 "Real" Pills)
Status: Completed Condition: Pelvic Pain; Headaches; Emotional

Post Operative Continuous Active Combination Sex Steroids for the Prevention of Recurrent Endometrioma Formation
Status: Withdrawn Condition: Endometrioma

Study of the Contraceptive Efficacy and Safety of a NOMAC-E2 Combined Oral Contraceptive (COC)(P06448)
Status: Terminated Condition: Contraception

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Exclusivity Expiration
Warner Chilcott
ethinyl estradiol; norethindrone acetate
TABLET; ORAL021871-001Feb 17, 2006RXYes5,552,394<disabled><disabled>
Warner Chilcott
ethinyl estradiol; norethindrone acetate
TABLET; ORAL021871-001Feb 17, 2006RXYes<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: LOESTRIN 24 FE

Drugname Dosage Strength RLD Submissiondate
norethindrone acetate/ ethinyl estradiol and ferrous fumarateTablets1 mg/0.02 mg and 75 mgLoestrin 24 Fe4/17/2006
« Back to Dashboard

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn